Cumberland Pharma Gets FDA Fast Track for Groundbreaking DMD Heart Treatment
Cumberland Pharmaceuticals receives FDA Fast Track designation for ifetroban, a promising new oral therapy targeting fatal heart disease in Duchenne muscular dystrophy patients.